Kanada - angielski - Health Canada

eli lilly canada inc - insulin glargine - solution - 100unit - insulin glargine 100unit - insulins

Kanada - angielski - Health Canada

eli lilly canada inc - insulin glargine - solution - 100unit - insulin glargine 100unit - insulins

Australia - angielski - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro -

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml;   - solution for injection - 100 u/ml - active: insulin lispro 100 u/ml   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml;   - solution for injection - 100 u/ml - active: insulin lispro 100 u/ml   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol sodium hydroxide water zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg; overage 0-3%);   - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg; overage 0-3%)   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg; overage 0-3%);   - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg; overage 0-3%)   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: hydrochloric acid; glycerol; phenol; water for injections; dibasic sodium phosphate heptahydrate; metacresol; zinc oxide; sodium hydroxide; protamine sulfate - indications: for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: zinc oxide; sodium hydroxide; hydrochloric acid; dibasic sodium phosphate heptahydrate; protamine sulfate; phenol; glycerol; water for injections; metacresol - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, solution - excipient ingredients: hydrochloric acid; dibasic sodium phosphate heptahydrate; glycerol; metacresol; zinc oxide; sodium hydroxide; water for injections - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.